Exelixis
EXEL
#1342
Rank
C$23.02 B
Marketcap
C$94.34
Share price
-3.60%
Change (1 day)
59.43%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): C$4.85

According to Exelixis's latest financial reports the company's current EPS (TTM) is C$4.96. In 2025 the company made an earnings per share (EPS) of C$4.14.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$4.8517.01%
2025C$4.14
2023C$0.9414.61%
2022C$0.82-22.97%
2021C$1.06100%
2020C$0.53-65.09%
2019C$1.52-53.91%
2018C$3.30333.96%
2017C$0.76-260.61%
2016C-$0.47-58.75%
2015C-$1.15-42.45%
2014C-$1.995.3%
2013C-$1.89

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
C$9.57 93.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
C$1.02-79.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
C$24.91 402.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
C$2.84-42.76%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
C$1.42-71.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$6.48 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
C$4.12-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
C-$20.38-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
C-$1.20-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA